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The TWIST1 embryonic transcription factor displays biphasic functions during the course of carcinogenesis. It facilitates
the escape of cells from oncogene-induced fail-safe programs (senescence, apoptosis) and their consequent neoplastic
transformation. Additionally, it promotes the epithelial-to-mesenchymal transition and the initiation of the metastatic
spread of cancer cells. Interestingly, cancer cells recurrently remain dependent on TWIST1 for their survival and/or
proliferation,making TWIST1 their Achilles’heel. TWIST1hasbeen reported to formeither homodimeric or heterodimeric
complexes mainly in association with the E bHLH class I proteins. These complexes display distinct, sometimes even
antagonistic, functions during development and unequal prometastatic functions in prostate cancer cells. Using a
tethered dimer strategy,we successively assessed the ability of TWIST1 dimers to cooperatewith an activated version of
RAS in human mammary epithelial cell transformation, to provide mice with the ability to spontaneously develop breast
tumors, and lastly tomaintain a senescence program at a latent state in several breast cancer cell lines.We demonstrate
that the TWIST1-E12 complex, unlike the homodimer, is an oncogenic form of TWIST1 in mammary epithelial cells and
that efficient binding of both partners is a prerequisite for its activity. The detection of the heterodimer in human
premalignant lesions by a proximity ligation assay, at a stage preceding the initiation of the metastatic cascade, is
coherent with such an oncogenic function. TWIST1-E protein heterodimeric complexes may thus constitute the main
active forms of TWIST1 with regard to senescence inhibition over the time course of breast tumorigenesis.
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The TWIST1 gene is aberrantly reactivated in a large set of solid
cancer types, including a variety of carcinomas, melanomas, sarcomas,
and neuroblastomas [1]. As a reminiscence of its embryonic
functions, this transcription factor was originally shown to promote
the metastatic dissemination of cancer cells through its ability to
trigger an epithelial-to-mesenchymal transition [2]. We and others
additionally highlighted its ability to alleviate the induction of fail-safe
programs (senescence, apoptosis) in response to oncogenic activa-
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cell neoplastic transformation in vitro and tumor initiation in vivo
[3–9]. Furthermore, cancer cells often remained dependent on
TWIST1 functions to protect them from latent senescence or
apoptosis [3,4,8–11]. Its oncogenic properties are mostly related to its
ability to downmodulate the activity of p53 [6,9,11,12] and to dampen
the expression of numerous cyclin-kinase inhibitors (p15INK4B,
p16INK4A p21CIP1), the relative contribution of these activities varying
according to the cellular context [3,4].
Basic-helix-loop-helix (bHLH) transcription factors were originally
classified into different categories based on their expression pattern,
partners, and structural features [13]. The TWIST1 protein belongs to
class II, which encompasses tissue-specific bHLH, such as MyoD.
These proteins heterodimerize with the ubiquitously expressed class I
bHLH proteins, termed E proteins [13]. They include the two splice
variants of the TCF3/E2A protein E12 and E47, the TCF4/ITF2, and
the TCF12/HEB transcription factors. All TWIST1-E heterodimers
have been shown to display similar functional properties [14]. The
TWIST1 protein also interacts with the class II bHLH transcription
factors HAND1 and HAND2 and additionally displays the property
to constitute functional homodimers, as originally demonstrated in
Drosophila [15]. The TWIST1 protein preferentially heterodimerizes,
providing a rationale for the similar limb formation defects triggered
by the enforced expression of the TWIST1-E12 heterodimer or of
the TWIST1 monomer [16–18]. Nonetheless, homodimerization is
privileged at low protein concentration (e.g., TWIST1 haploinsuffi-
ciency in Saethre-Chotzen patients), in the presence of ID HLH
proteins which titrate E proteins, or following the phosphorylation of
residues located in the helix I of TWIST1 (i.e., Thr121 and Ser123) by
protein kinase A [14,19,20]. Point mutations preventing the
posttranslational modification of these residues (TS121-123AA) or
mimicking their constitutive phosphorylation (TS121-123ED) were
demonstrated to functionally mimic the TWIST1 homodimer and
heterodimer, respectively [16]. The phosphoregulation of TWIST1was
additionally shown to influence its affinity for E-boxes in a cis-element–
dependent manner [20]. Posttranslational modifications of TWIST1
thus have an impact on dimer choice and on the downstream activation
of targeted genes [21]. The contribution of these complexes to the
embryonic TWIST1 functions has been largely explored using tethered
dimers, the reliability of this approach being unquestionably established
through successful in vivo complementation assays [15,16,19]. The
validity of this strategy was also supported by the demonstration that the
tethered TWIST1~E12 dimer binds DNA and transactivates reporter
genes similarly to when TWIST1 and E12 are expressed as separated
polypeptides [15,20]. Exploiting this tethered dimer strategy unveiled
differential and even antagonistic properties of the TWIST1 complexes
during embryonic development, demonstrating the key role of the
TWIST1 partner in determining and regulating TWIST1 functions.
Whether the balance between these dimers also modulates TWIST1
functions during tumorigenesis remains relatively unexplored. Enforced
expression of tethered TWIST1~TWIST1 or TWIST1~E12 dimers in
prostate cancer cell lines led to the conclusion that the prometastatic
properties of TWIST1 are allotted to the heterodimeric TWIST1
complex [22]. Their contribution to the malignant transformation
nonetheless still remains to be determined. Moreover, identifying the
TWIST1 complex implicated in the escape from fail-safe program
and upon which cancer cells are dependent for their proliferation
and survival constitutes an essential step in the development of novel
therapeutic strategies aiming at eradicating cancer cells throughTWIST1 inactivation. To tackle this question, we employed this
tethered dimer strategy to assess the oncogenic potentials of both
TWIST dimers in vitro and in vivo.
Material and Methods
DNA Constructs
The EcoR pBabe Zeo, ER-H-RASG12V pLNCX2-Neo, and
H-RASG12V pbabe-Puro retroviral construct and the VIM1-luciferase
reporter have been previously described [23–26]. The tethered dimers
were generated by polymerase chain reaction (PCR) using FLAG-
human TWIST1 [3] and E12 expression constructs [27] as templates.
The strategy employed to generate the tethered dimers is described in
detail in the Supplementary Information section. The shRNA TWIST1
A pLKO.1 lentiviral construct was previously described [3]. The shRNA
TWIST1 B pSIREN (5′-CTCTGGAGCTGGATAACTAAA-3′)
retroviral construct was kindly provided by Patrice Lassus (IGMM,
Montpellier). The shRNA TCF3 pLKO.1 was supplied by Sigma.
Mouse Strains
Animal maintenance and experiments were performed in a specific
pathogen-free animal facility, “Anican,” in accordance with the animal
care guidelines of the European Union and French laws and were
validated by the local Animal Ethic Committee (CECAAP). The
CAG-LSL-Twist1-Twist1 or CAG-LSL-Twist1-E12 (FVB/NJ genetic
background) [19] was crossed with the WAP-Cre (whey acidic protein
promoter [28]) mouse strain [B6.Cg-Tg(Wap-Cre)11738 Mam,
obtained from the mouse models of Human Cancers Consortium and
back-crossed to the FVB/NJ genetic background]. Cohorts of
multiparous female WAP-Cre; Twist1-Twist1 and WAP-Cre;
Twist1-E12 mice (with two rounds of lactation) were generated.
Genotyping was performed on genomic DNA from tails using the
5′-AATGAAATGGAGAGCTTGGGCGAC-3′ and 5′-CATCACT
CGTTGCATCGACC-3′ primer pair for the WAP-Cre transgene
and 5′-GCAAGCGCGGCAAGAAATCTG-3′ and 5′-CCCGTTCA
AGTCCTCTTCAGAAATGAC-3′ primer pair for the Twist1 trans-
gene as described previously [19,28].Mice were monitored twice a week
for tumor incidence. End points were based on tumor diameter (up to
1.5 cm) unless natural death occurred. Mice were euthanized by CO2
inhalation. Tumors were fixed in 10% phosphate-buffered formalin for
24 hours and embedded in paraffin. Mammary gland, lung, liver,
kidney, and spleenwere collected either to check formalignant lesions or
to assess potential metastatic dissemination.
Cell Culture
HMEC-hTERT cells and derived cells were cultured as described
previously [7]. The Hs578T, MDA-MB-436, MDA-MB-231, and
BT-474 breast cancer cell lines and HEK293T were provided by the
ATCC and cultured according to the supplier’s instructions.
Protein Analysis and Immunohistochemistry
Cells extracts were performed in radioimmunoprecipitation assay
(RIPA) buffer [100 mMNaCl, 1%NP40, 0.1% sodium dodecyl sulfate
(SDS), 50 mM Tris pH 8] supplemented with protease (Roche) and
phosphatase inhibitor cocktails (Sigma) and clarified by centrifugation.
Proteins were analyzed by Western blot using the monoclonal
anti-TWIST1 2C1a (Abcam), anti-p21CIP1 clone SX118 (Dako),
and anti-HEB A9 (Santa Cruz Biotechnology) and the polyclonal
anti-TWIST2 (proteintech), anti-E2AV18, anti-ITF2 K12, anti-H-RAS
C20, anti-p15INK4B C20, anti-p16INK4A H156, p-histoneH3 (Ser10)-R
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antibodies and horseradish peroxidase–conjugated secondary antibodies
(Dako). Antigen-antibody complexes were revealed with the Wester-
n-blotting Luminol reagent (Santa Cruz Biotechnology).
Analysis of TWIST1 by immunohistochemistry in mouse breast
carcinomas was performed as described previously [7] using the
monoclonal anti-TWIST1 2C1a (Abcam).
Gene Expression Analysis
RNA preparation and reverse transcription were performed as
described previously [29]. Real-time PCR intron-spanning primers
were designed with the primer3 software. The HPRT1 housekeeping
gene was used for normalization. The combinations of primers used
are listed in the Supplementary Information section.
Retroviral Infections, SA-β-Galactosidase, Growth Curves, and
Soft-Agar Colony Assays
Enforced expression of H-RASG12V and/or TWIST1 proteins was
performed through retroviral infections as described previously [29].
Briefly, cells were “murinized” by expressing the ecotropic receptor
[24,30] before being infected with retroviral expression constructs 48
hours later. Selection was initiated 24 hours post–second infection
with puromycin (0.5 μg/ml) or neomycin (100 μg/ml).
shRNA TWIST1 lentiviral particles were generated through the
co-transfection of 293T cells with pLKO.1, pCMV ΔR8.91
(gag-pop-Tat-Rev) [31], and phCMVG-VSVG (env) [32] expres-
sion constructs, and shRNA TWIST1 retroviral particles were
generated through the transfection of HEK293GP cells with
pSIREN and phCMVG-VSVG (env) expression constructs using
the calcium phosphate precipitation technique. TWIST1 knock-
down was achieved via double retroviral (shRNA TWIST1 B
pSIREN) or lentiviral (shRNA TWIST1 A pLKO.1) infections at
48-hour intervals. Over 90% of cells were infected. Consequences of
TWIST depletion on cell survival and proliferation were assessed
in the absence of selection. Activation of ER-RASG12V with 4-OH-
tamoxifen (4-OHT, 625 nM, Sigma Aldrich) was specifically
performed in medium supplemented with 1 mM D-glucose. Three
days later, cells were washed twice with PBS, either fixed in 3%
formaldehyde and stained with crystal violet or tested with a
SA-β-galactosidase assay [33]. Transformation assays were performed
1 week postinfection (TWIST1 transduction) or post–second infection
(RAS + TWIST transduction), as described previously [29].
Immunofluorescence
A total of 104 cells were seeded on a 12-well IBIDI-chamber slide,
fixed in 4% formaldehyde (Sigma) for 15 minutes, washed with 1%
bovine serum albumin (BSA) in PBS buffer, and permeabilized in
0.1% Triton 100× (Sigma) and 1% BSA in PBS buffer at room
temperature for 10 minutes. The cells were then washed three times
with 1% BSA in PBS buffer and incubated with the anti-TWIST1
2C1a primary antibody (Abcam, diluted 1/100 in 0.5% BSA in PBS
buffer) overnight at 4°C. Following extensive washing in 1% BSA in
PBS buffer, cells were incubated with fluorescein isothiocyanate–
conjugated Alexa goat anti-mouse antibody (Life Technology, 1/600
in 0.5% BSA in PBS buffer) for 30 minutes at room temperature.
Nuclei were stained with Hoechst 5 mg/ml in 0.5% BSA in PBS
buffer for 10 minutes and mounted with Fluoromount-G (South-
ernBiotech). Images were taken on an immunofluorescence
microscope (Leica) at identical exposure times.Immunoprecipitation
HEK293T cells were transfected with wild-type or mutant
FLAG-tagged TWIST1 and/or MYC-tagged E12 expression constructs
using the calcium-phosphate technique. Cells were lysed 36 hours
posttransfection in a 50-mM Tris-HCl pH 7.4, 150-mMNaCl, 1-mM
EDTA, and 1% Triton buffer supplemented with protease inhibitors
(Roche), cleared by centrifugation, and incubated with an anti-FLAG
M2 resin (Sigma-Aldrich). After intensive washing to eliminate
nonspecific binding, the resin was resuspended in Laemmli buffer and
boiled for 3 minutes. After elimination of the beads by centrifugation,
samples were reduced by adding β-mercaptoethanol and separated on
SDS–polyacrylamide gel electrophoresis. Proteins were analyzedwith the
murine monoclonal anti-TWIST1 C2a antibody (Abcam) and the
rabbit polyclonal V18 E2A antibody (Santa Cruz Biotechnology).
Immunoprecipitation of endogenous E12 protein by ectopically
expressed FLAG-TWIST1 was performed in HMEC-hTERT cells. A
total of 2 × 106 cells were resuspended in an extraction buffer (20 mM
Tris pH 8, 125 mMNaCl, 1 mM EDTA, 0.5%NP40) supplemented
with protease inhibitors (Roche), sonicated, and cleared by centrifuga-
tion. Protein extracts were diluted in a final 20-mM Tris pH 8 buffer
containing 125 mMNaCl, 1 mMEDTA, NP40 0.125%, and glycerol
10% and successively incubated in the presence of 4 μg ofM2α-FLAG
antibody (Sigma) for 4 hours at 4°C and protein-A sepharose beads
(protein A sepharose 4B, InVitrogen) for 1 hour. After intensive
washing in a 20-mM Tris pH 8 buffer containing 125 mM NaCl,
1 mMEDTA, NP40 0.1%, and glycerol 10%, beads were resuspended
in Laemmli buffer (in absence of β-mercaptoethanol) boiled at 95°C for
3 minutes. After elimination of the beads by centrifugation, samples
were reduced by adding β-mercaptoethanol and separated on SDS–
polyacrylamide gel electrophoresis.
Proximity Ligation Assay
Human ductal in situ carcinoma (DCIS) samples were obtained
through the Biological Resource Center of the Centre Léon Bérard
with the agreement of the ethical review board of the Centre Léon
Bérard. Samples were used with the patient’s written informed
consent. The present study was approved by the ethical review board
of the Centre Léon Bérard. DCIS samples were selected on the basis
of TWIST1 protein detection, as previously reported [7].
After deparaffinization and rehydratation, tissue sectionswere boiled in
a 10-mM pH 6 citrate buffer for 40 minutes. After saturating unspecific
binding sites for 20 minutes with a 1% BSA PBS buffer, sections were
incubated overnight with the mouse monoclonal anti-TWIST1
Twist2C1a (Abcam) and the rabbit polyclonal anti-E2A N-649 (Santa
Cruz) antibodies in a 0.5% BSA in PBS buffer. Incubation with PLA
probes, ligation, and amplification steps were performed according to the
manufacturer instructions (Duolink In Situ kit, Sigma). The specificity of
the signal was confirmed using paraffin-embedded MDA-MB-436,
Hs578T (TWIST1 positive, E12 positive), and HMEC-hTERT
(TWIST1 negative, E12 positive) mammary cells in which TWIST1 or
TCF3 (the two E2A protein variants E12 and E47 encoding gene)
were specifically knocked down through RNA interference. Number of
dots per cell was assessed using the ImageJ software.
Results
Design of Wild-Type and Mutant Tethered TWIST1 Dimers
Because both HAND1 and HAND2 genes were found to be
transcriptionally inactive in breast cancer cells and because the TCF3/
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cancer cell lines employed in this study, as assessed by Western blot
(Figure S1A), the experiments were performed either with homodimeric
(TWIST1-TWIST1, hereafter named T~T) or heterodimeric (TWIS-
T1-E2A E12, hereafter named T~E) tethered dimers. Following
previous studies [15,19,20,22], the E2A splice variant E12 was
employed as the model for TCF3/E2A proteins. Tethered dimers were
generated by linking the two partners with a flexible glycine-serine
polylinker, also used in previous studies [15,19,20,22], and the
TWIST1 protein was tagged at the N-terminus with a single FLAG
peptide, a position that we previously confirmed does not interfere with
TWIST1 oncogenic functions [3] (Figure S1B). The production and
correct nuclear localization of the resulting tethered dimers were
validated (Figure S1C). Noticeably, C-terminal truncated subproducts
(revealed with both anti-TWIST1 and anti-FLAG antibodies) were
detected. Very similar subproducts were revealed with the functional
murine MYC-tagged T~T and MYC-tagged T~E forced dimers
generated in the laboratory ofD. Spicer [14] (Figure S1D). In particular,
the detection with the T~T dimer of a predominant subproduct with a
molecular size close to the monomer likely reflects a difference in the
accessibility of a consensus caspase 3/7 cleavage site present in the
C-terminal of TWIST1 within the two tethered dimers. Cleavage
of TWIST1 by caspase 3 was originally reported in apoptotic cells
and was quickly followed by its proteasome-mediated degradation
[34]. It is, therefore, very likely that the cleavage occurs during
protein extraction.Figure 1. Homo- and heterodimeric TWIST1 complexes unequally a
epithelial cells. (A) HMEC-hTERT cells were sequentially infected wit
TWIST1, the homodimeric TWIST1~TWIST1 tethered dimer, or the w
dimer. (B) In the absence of TWIST1, the activation of the ER-H-RA
senescence as shown in the SA-β-galactosidase assay and the accu
(p21) as assessed by Western blot. (C and D) Five days postactivati
through a crystal violet staining (C), and p21CIP1 (p21), p15INK4B and T
quantification with respect to MOCK cells is indicated.As the study progressed, additional mutants were generated including
the T R154P~E heterodimer (hereafter named T RP~E) to confirm the
need of the interaction between both partners to generate an active
tethered heterodimer. The R154P mutation was previously reported to
disrupt the TWIST1-E2A protein interaction [35], and this was herein
confirmed by performing a co-immunoprecipitation assay (Figure S2A).
Insertion of this mutation into the T~E tethered dimer (T RP~E) did not
have an impact on its nuclear sublocalization (Figure S2B) but, as
anticipated, abrogated the ability of the fusion protein to activate the
TWIST1-targeted vimentin (VIM) gene in a reporter assay (Figure S2C).
A TWIST1 K145E-TWIST1 K145E (T KE~T KE) tethered dimer was
also generated as an inactive version of the T~T tethered dimer. The
Lys145 residue plays a determining role in stabilizingTWIST1 complexes
on theDNAby contributing to the establishment of the interhelical loops
and by directly interactingwith oxygen atoms ofDNAbases [36,37]. The
K145E mutation thus affects the global structure of TWIST1 complexes
and abrogates TWIST1 DNA binding properties [38].
The TWIST1 Dimers Unequally Alleviate Oncogene-Induced
Senescence in Human Mammary Epithelial Cells
To compare the ability of both TWIST1 dimers in preventing
oncogene-induced senescence (OIS), immortalized and nontrans-
formed human mammary epithelial cells (HMEC-hTERT) were
sequentially infected with retroviral vectors encoding either for an
inducible activated version of HRAS (ER-H-RASG12V) or for TWIST1
(monomer T, T~T or T~E dimer) (Figure 1A). Activation of thevoid RAS-induced senescence in immortalized human mammary
h the inducible ER-H-RASG12V fusion protein and with monomeric
ild-type (wt) or mutant (RP) TWIST1~E12 heterodimeric tethered
SG12V protein, using 4-OHT, was associated with the induction of
mulation of the cyclin-kinase inhibitors p15INK4B (p15) and p21CIP1
on of ER-H-RASG12V using 4-OHT, cell proliferation was assessed
WIST1 proteins were analyzed by Western blot (D). Relative signal
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triggered a senescence program, as revealed by the permanent
proliferation arrest and the detection of a SA-β-galactosidase activity
(Figure 1B). While the CDKN2A-ARF locus is methylated in
HMEC-hTERT cells [39–41], commitment into senescence was
associated with an accumulation of p15INK4B (p15) and p21CIP1/WAF1
(p21) (Figure 1B). In line with our previous observations [3], enforced
expression of the TWIST1 monomer successfully prevented the
activation of cyclin-kinase inhibitors and sustained cell proliferation, as
assessed in a crystal violet coloration assay (Figure 1, C and D). The
heterodimer turned out to be functionally active in this assay and
the homodimer inactive (Figure 1, C and D), suggesting that the
dimerization between TWIST1 and E protein partners is a prerequisite
to carry out this function. To support this hypothesis, we observed that
the disruption of the partner interaction through the insertion of the
R154P point mutation in TWIST1 abolished T~E activity (Figure 1, C
andD). Collectively, this assay demonstrated that both monomeric and
tethered heterodimers similarly preventOIS, supporting the concept that
ectopically expressed TWIST1 can form heterodimers with endogenous
E proteins [17,18]. Indeed, ectopic TWIST1 was confirmed to
immunoprecipitate the endogenous E12 protein (Figure S3). Of note,
in light of the absence of activity of the TWIST1 homodimeric complex,
the functionality of the fusion protein was further controlled by assessingFigure 2. The heterodimeric TWIST1 complex displays oncogenic pro
infected with TWIST1 (T~T, wt, or mutant T~E) and H-RASG12V r
established cell lines was assessed in a soft-agar colony formation
performed in triplicates are shown. (B) Analysis of TWIST1 and RAS pr
potential in vivo. The enforced expression of Twist1 in luminal com
CAG-LSL-Twist~Twist1 or CAG-LSL-Twist1~E12 with WAP-Cre mice
number of mice spontaneously developing breast carcinoma during th
Plot boxes indicating the expression of ectopic TWIST1 transcripts in t
Levels were expressed relative to the housekeeping HPRT1 gene tran
carcinoma. (E, right panel) Example of TWIST1 staining in a metaplasits ability to transactivate a set ofTWIST1 targeted genes, selected on the
basis of previous studies [7,42]. As shown in Figure S4, the homodimer
was confirmed to be functional. As an internal control, the insertion
of the K145E mutation (T KE~T KE tethered dimer), described to
abolish the TWIST1 DNA binding capability [38], annihilated its
transactivation potential.
To strengthen the differences observed between the two TWIST1
complexes, we next assessed their ability to cooperate with the
H-RASG12V protein in promoting the neoplastic transformation of
HMEC-hTERT cells. To this end, cells were sequentially infected with
TWIST1 and constitutive H-RASG12V retroviral expression constructs.
Whereas the sole expression of the TWIST1 tethered dimers failed to
transform cells, concomitant production of H-RASG12V and the active
heterodimeric complex successfully transformed cells, as assessed in a
colony formation assay (Figure 2, A and B). Neither the homodimeric
T~T complex nor the inactive form of the T~E complex (T RP ~E) was
found to be functional in this second assay.
The enforced Expression of the T~E Tethered Dimer Induces
the Spontaneous Development of Breast Carcinoma in Mice
Next, we validated the different oncogenic activities observed between
the two TWIST1 complexes in vivo. We previously reported that the
combined production of either the murine monomeric TWIST1 or theperties in vitro and in vivo. (A) HMEC-hTERT cells were sequentially
etroviral expression vectors. The transformation potential of the
assay. Mean of numbered colonies and SD of one experiment
oteins by Western blot. (C–E) Assessment of the TWIST oncogenic
mitted mammary epithelial cells was achieved by crossing either
. (C) Kaplan-Meier tumor-free survival. (D) Histogram indicating the
eir lifespan. Stars mark mice with two breast tumors. (E, left panel)
umors as assessed by quantitative reverse transcription (qRT)–PCR.
script and were normalized against wild-type mice–derived breast
tic spindle cell carcinoma.
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luminal committed epithelial cells induced breast tumor development in
the first 5 months with a complete penetrance [7]. However, not a single
one of the three mice examined, coexpressing the homodimer T~T and
K-RASG12D, developed breast tumors within the same period of time,
suggesting that the homodimer failed to cooperate with RAS in
promoting tumor initiation (G.W. Hinkal, unpublished data). To
strengthen this result, we examined whether the ectopic expression of
T~T or T~E in the absence of an oncogenic insult was sufficient to
promote breast carcinogenesis, with an anticipated lower penetrance and
extended latency to accumulate requested secondary events. T~Tor T~E
production was enforced in luminal committed cells through the
generation of WAP: Twist1~Twist1 and WAP: Twist1~E12 mice
(producing the murine T~T or T~E fusion proteins under the control of
the whey acidic protein promoter) by crossing either the CAG-LSL-
Twist1~Twist1 or CAG-LSL-Twist1~E12 mouse strain with the
WAP-Cre mouse strain [19,28]. Full activation of the WAP promoter
was assured by two consecutive lactations. As shown in Figure 2, C–E,
T~E-producing mice were found to develop breast carcinomas with a
higher frequency (37.9%, n = 29) and a shorter latency than
T~T-producing mice (18.1%, n = 14) and control littermates (6.2%,
n = 16). Tumor phenotypes were found to be heterogeneous and
classified [43] as (i) adenosquamous, (ii) metaplastic spindle cell, (iii)
papillary and cribriform, (iv) solid and cribriform, and (v) adenosqua-
mous carcinomas (Table S1). No secondary tumor site was detected.
Collectively, these observations support our conclusion that the
heterodimeric complexes are the oncogenic forms of TWIST1 in
mammary epithelial cells.
The Heterodimeric TWIST1-E12 Complex Is Detected in
Human Breast Premalignant Lesions
If the assumption that the heterodimeric TWIST1 complex plays a
role in malignant transformation, breast cancer cell survival, and
proliferation is correct, we would expect that this complex would already
be detectable in DCIS before the initiation of the metastatic cascade.We
thus assessed TE complex formation through a proximity ligation assay
(PLA), selecting cases previously defined as TWIST1-positive or
-negative by immunohistochemistry [7]. Experimental conditions were
established in mammary carcinoma cell lines, and the specificity of the
signal was confirmed by turning down the expression of either the
endogenous TWIST1 or TCF3 (the E12/E47 proteins-encoding gene)
through RNA interference. Depletion in the TWIST1 and E2A proteins
significantly reduced the number of dots detectable in the TWIST1-
positive MDA-MB436 (8.8 ± 1.1 dots/cell to 4.9 ± 1.0 and 1.6 ±
1.5 dots/cell, respectively) and Hs578T (9.8 ±3.1 dots/cell to 3.1 ± 1.9
and 2.2 ±1.7 dots/cell, respectively), whereas the number of dots/cell
remainedb1 in TWIST1-negativeHMEC-hTERT cells (Figure S5). As
shown in Figure 3, the TE complex was invariably detected in all
TWIST1-positive DCIS, whereas no signal was detected in the control
samples, namely, TWIST1-negative DCIS and normal mammary
glands. The detection of the TE complex in premalignant lesions is thus
compatible with its role in the inhibition of a fail-safe program.
The TWIST1-E12 Heterodimeric Complex, Unlike the
Homodimeric TWIST1 Complex, Complements the Loss of
the Endogenous TWIST1 Protein in Sustaining Mammary
Epithelial Cancer Cell Proliferation
By lowering the activity of oncosuppressive pathways and of the
cell cycle control machinery, the TWIST1 protein not only favors thecell neoplastic transformation but also protects cancer cells from
latent OIS and/or apoptosis [3–5,8–10]. To assess the contribution of
TWIST1 dimers in these secondary activities, we selected a shRNA
targeting the 3′-untranslated sequences of the endogenous TWIST1
RNA, which are absent from the heterodimer cDNAs, to inhibit
endogenous TWIST1 expression and performed complementation
assays with the tethered dimers. We confirmed that this shRNA
(shRNA TWIST1 B), similarly to the shRNA used in our previous
studies (shRNA TWIST1A [3]), induced a proliferation arrest (as
assessed by a crystal violet coloration assay and the amount of
phospho-Ser10 histone H3) and triggered a senescence program, as
revealed by the detection of a SA-β-galactosidase activity (Figure 4), in
all three breast cell lines tested (basal-B/claudin-lowMDA-MB-436 and
Hs578T cell lines and the luminal B BT-474 cell line). The permanent
growth arrest was invariably associated with an accumulation of
p15INK4B (p15) and p21CIP1 (p21) cyclin-dependent kinase inhibitors,
p16INK4A (p16) remaining undetectable (Figure 4). No trace of cleaved
caspases-3 or PARP fragments was detected, excluding a concomitant
apoptosis induction (data not shown). To evaluate the contribution of
both the homodimeric and heterodimeric TWIST1 complexes,
MDA-MB-436 cells were next sequentially infected with TWIST1-
expressing constructs (using a monomeric TWIST1 cDNA lacking
3′-untranslated sequence as an internal positive control) and depleted in
endogenousTWIST1 throughRNA interference. As shown inFigure 5,
similarly to the ectopically expressed TWIST1 monomer, the
heterodimeric T~E complex avoided cyclin-kinase inhibitor accumu-
lation and sustained cell proliferation. As anticipated, the inactive T~E
variant (T RP ~E) failed to do so. The T~T homodimer also failed to
complement the endogenous TWIST1 functions. Similar results were
obtained in the two additional Hs578T and BT-474 cell lines (Figure
S6). These data unambiguously demonstrated that the T~E heterodi-
meric complex is necessary to prevent OIS and to maintain the
senescence program in a latent state in mammary epithelial cells.
Discussion
The embryonic transcription factor TWIST1 displays pleiotropic
functions during carcinogenesis, promoting the neoplastic transforma-
tion of cells and tumor initiation, on the one hand, and the metastatic
spread of cancer cells through EMT induction, on the other hand [1].
Determining whether these functions rely on the activities on various
TWIST1 complexes or whether the oncogenic and prometastatic
properties are conferred upon a single complex is essential to further
understand the TWIST1 functions as well as to design strategies to
inactivate the transcription factor. By using a tethered dimer approach,
previously proven to delineate the TWIST1 complex functions in vitro
as well as in vivo, we demonstrated that the TWIST1-E12 heterodimer
efficiently avoided OIS in mammary epithelial cells. Furthermore, its
enforced expression complements the activity of the endogenous
TWIST1 protein in keeping cyclin-kinase inhibitors under a threshold
compatible with breast cancer cell proliferation. In comparison, the
homodimeric complex failed to do so, highlighting the pivotal role of the
TWIST1 partner in regulating its oncogenic functions. To support this
conclusion, the monomeric TWIST1 protein and the heterodimeric
TWIST1 complex were found to efficiently cooperate with RAS in
promoting breast carcinogenesis in vivo [7]. Despite the limited number
of mice examined, the absence of pathology observed when the
homodimeric TWIST1 complex was combined with RAS demonstrated
that T~T was less efficient than T~E in promoting tumor initiation in
this context (G.W. Hinkal, unpublished results). The tendency of mice,
Figure 3. The heterodimeric complex is detectable in breast premalignant lesions, as assessed in a PLA. Assessment of the TWIST1-E12
heterodimeric complex in a PLA in TWIST1-positive and TWIST1-negative DCIS [7]. Healthy mammary gland was used as a control. Each
single dot corresponds to the detection of a TE complex.
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develop breast carcinoma with a higher frequency than their T~T
counterparts and control littermates further supports this conclusion.
Several bHLH transcription factors are known to heterodimerize
with TWIST1, including the TCF3/E2A splice variants E12 and E47,
the TCF4/ITF2, the TCF12/HEB, and the HAND proteins. As the
HAND genes were found to be transcriptionally inactive in the
examined breast cancer cells (Figure S1), we focused on E proteins,
using E12 as a prototype. Considering the degree of homology in their
bHLH domains (81.8% identity with TCF3/E2A E47 splice variant,89.1% identity with TCF4/E2-2, and 92.7% identity with TCF12/
HEB), it is likely that all of these complexes display similar oncogenic
properties. E2A proteins are the predominant E proteins expressed in
the breast cancer cell lines employed in the present study, as assessed by
Western blot (Figure S1A). Unfortunately, we cannot exclude that
additional TWIST1 bHLH protein partners also contribute to its
oncogenic activity. For example, the TWIST1-related TWIST2 protein
is expressed in the two basal-B/claudin-low breast cancer cell lines
examined (Figure S1A). Although coexpression of both transcription
factors at the cellular level remains to be demonstrated, the two proteins
Figure 4. Depletion in TWIST1 reactivates latent OIS in breast cancer cells. Breast cancer cells (A, MDA-MB-436; B, Hs578T; C, BT-474)
were depleted in TWIST1 through RNA interference (shRNA TWIST1 A or B). (Left panels) Two days postinfection, cells were seeded at
low density and stained after 3 days with crystal violet or assessed for their SA-β-galactosidase activity. (Right upper panels) Analysis of
the level of the endogenous TWIST1 transcripts by qRT-PCR. Levels were expressed relative to the housekeeping HPRT1 gene transcript
and were normalized against uninfected cells. Mean, SD and Student’s t test of one experiment performed in triplicate are shown. (Right
lower panels) Analysis of Ser10-histone H3, p15INK4B (p15), p16INK4A (p16), p21CIP1 (p21), and TWIST1 by Western blotting (relative signal
quantification with respect to shRNA control infected cells is indicated). “−” means below the threshold.
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TWIST1-E12 complex was additionally shown to drive the prometa-
static activity of TWIST1 in prostate cancer cells [22], suggesting that
the TWIST1-E complexes are the active forms of TWIST1 with regard
to tumorigenesis, promoting both tumor initiation and progression.
Using a PLA, we confirmed that the heterodimer is detectable in DCIS
before the metastatic cascade is initiated (Figures 3 and S5).Because the ectopic expression of the tethered dimer T~T did not
affect breast cancer cell proliferation, it is possible that the homodimeric
complex does not display transdominant negative properties, at least
with regard to the functions and cellular models considered in this
study. The balance between the two complexes rather spatially and
temporally controls the amount of heterodimeric complex and, thereby,
the oncogenic and prometastatic properties of TWIST1. To support
Figure 5. A fully active TWIST1-E12 heterodimeric complex is required to complement the endogenous TWIST1 function in sustaining
MDA-MB-436 breast cancer cell proliferation. (A) MDA-MB-436 breast cancer cells were sequentially infected with T, T~T, or T~E (either
wild-type or RP mutant) retroviral expression vectors and depleted in endogenous TWIST1 through RNA interference (shRNA TWIST1B).
Of note, the shRNA targets 3′-untranslated sequences absent from ectopically expressed TWIST1 constructs and thus specifically turns
down the endogenous TWIST1 expression. (B) Cells were seeded at low density 48 hours post–second infection and stained with crystal
violet 3 days later. (C) Analysis of the level of expression of endogenous TWIST1 by qRT-PCR. Levels were expressed relative to the
housekeeping HPRT1 gene transcript and were normalized against uninfected MDA-MB-436 cells. Mean, SD, and Student’s t test of one
experiment performed in triplicate are shown. (D) Analysis of p15INK4B (p15), p21CIP1 (p21), and TWIST1 proteins by Western blot (relative
signal quantification in respect to MOCK cells is indicated).
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the TWIST1 homodimer were shown to suppress the TWIST1-
driven invasive properties and to favor secondary site colonization
through the induction of a mesenchymal-to-epithelial transition
[45,46]. Interestingly, in both Caenorhabditis elegans and mouse
development, respectively, the HLH8 (the C. elegans TWIST
ortholog) andHAND1 homodimeric complexes were found to play a
key role, and the heterodimers’ functions were restricted to that of
counterbalancing their activity [47,48]. The relative contribution of
bHLH complexes during embryonic development and senescence
inhibition over the time course of breast carcinogenesis may thus be
inverted. Nonetheless, the ability of the homodimer to modulate
downstream targeted genes suggests that it might also display
unrelated and yet-uncharacterized protumoral properties.
In numerous tumor models, cancer cells were shown to remain
dependent on TWIST1 to sustain proliferation [3,4,8–11]. We now
extend this observation to EMT-committed basal-B breast cancer cells
(such asMDA-MB-436 andHs578T), which express a large spectrum of
EMT inducers including ZEB1 and TWIST2. ZEB1, similarly toTWIST1, has been demonstrated to downregulate the expression of
INK4B and CIP1 and to prevent EGFR-driven OIS in lung cancer cells
[49,50]. TWIST1 and TWIST2 were also shown to similarly
downregulate RB and p53 pathways [3]. The observed lack of
complementation between the proteins in these breast cancer cells either
suggests cell type–specific regulations (e.g., posttranslational regulations)
or unveils yet-unidentified TWIST1-dependent properties. The key
regulators leading to the specificity of the genetic program driven by
TWIST1 complexes remain to be defined. Of note, a tandem E-box
separated by a 5-nucleotide spacer was recently shown to be specifically
recognized by the TWIST1-E2A complexes (similarly with both E2A
splice variants), a tetrameric complex formed and stabilized through the
interaction between the α-helixes of the WR domain of TWIST1
proteins [51]. Enforced expression of the T~E heterodimer in
HMEC-hTERT cells affected the expression of a limited number of
genes (data not shown), suggesting that the tethered dimer strategy avoids
titration of bHLH factors. This experimental approach may lead the way
to defining the TWIST1-E complex downstream targeted genes and to
exploring their contribution to the oncogenic activity of TWIST1.
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